{"id":4812,"date":"2025-12-16T15:53:13","date_gmt":"2025-12-16T07:53:13","guid":{"rendered":"https:\/\/credevo.com\/s\/?page_id=4812"},"modified":"2026-01-05T19:13:09","modified_gmt":"2026-01-05T11:13:09","slug":"lurasidone-hydrochloride-bioequivalence-study-protocol","status":"publish","type":"page","link":"https:\/\/credevo.com\/s\/lurasidone-hydrochloride-bioequivalence-study-protocol\/","title":{"rendered":"Lurasidone Hydrochloride Bioequivalence Study Protocol"},"content":{"rendered":"\n
\n

With Lurasidone (Latuda) generating over $4 billion<\/strong> by 2022 and maintaining blockbuster-level performance within the $20+ billion<\/strong> global antipsychotic drug market, key patents expired in 2023-2024 across major markets, with generics already entering the space. The atypical antipsychotic market is large and expanding, driven by chronic schizophrenia and bipolar therapy needs. Lurasidone stands as one of the most BE-friendly CNS molecules, featuring linear pharmacokinetics and predictable absorption that enable fast, low-risk bioequivalence pathways. This ready-to-use protocol provides an instant 6-8 week<\/strong> head start for manufacturers looking to capture market share in this high-value CNS opportunity as patent expiry varies by territory, opening ongoing generic opportunities.<\/p>\n<\/blockquote>\n\n\n\n

<\/div>\n\n\n\n
\"Latuda<\/figure>
\n

Overview<\/strong>: Lurasidone Hydrochloride (Latuda) is used for the treatment of schizophrenia in adolescents and adults, and for bipolar depression as monotherapy in youth or as adjunctive therapy with lithium or valproate in adults, targeting depressive episodes without triggering mania. It is an atypical antipsychotic that selectively antagonizes dopamine D2\/D3 and serotonin 5-HT2A\/5-HT7 receptors while partially agonizing 5-HT1A receptors to balance neurotransmitters with minimal metabolic side effects. A bioequivalence study confirms that generic formulations are equivalent to the reference product in terms of systemic exposure and pharmacokinetic profile.<\/p>\n<\/div><\/div>\n\n\n\n

<\/div>\n\n\n\n
<\/div>\n\n\n\n

Download the complete, submission-ready BE protocol with all technical details<\/p>\n\n\n\n

What This Protocol Includes<\/p>\n\n\n\n

\n
\n
    \n
  • Study Synopsis<\/li>\n\n\n\n
  • Study Design Narrative<\/li>\n\n\n\n
  • PK Parameter Definitions (AUC, Cmax<\/sub>, Tmax<\/sub>, t\u00bd)<\/li>\n\n\n\n
  • Safety and AE\/ SAE Reporting<\/li>\n\n\n\n
  • Sampling Time Points<\/li>\n\n\n\n
  • Schedule of Assessments<\/li>\n<\/ul>\n<\/div>\n\n\n\n
    \n
      \n
    • Washout period<\/li>\n\n\n\n
    • Scientific Rationale & Regulatory Justification<\/li>\n\n\n\n
    • Dosing & Administration<\/li>\n\n\n\n
    • Inclusion\/ Exclusion Criteria<\/li>\n\n\n\n
    • Sample Handling <\/li>\n\n\n\n
    • Statistical Considerations<\/li>\n<\/ul>\n<\/div>\n<\/div>\n\n\n